Tech Company Financing Transactions
IsoBio Funding Round
ASP Isotopes participated in a $5 million Seed funding round for IsoBio. The round was announced on 7/28/2025.
Transaction Overview
Company Name
Announced On
7/28/2025
Transaction Type
Venture Equity
Amount
$5,000,000
Round
Seed
Investors
Proceeds Purpose
The funding will support IsoBio's development of antibody-isotope conjugates (AICs), which combine monoclonal antibodies with radioisotopes to target cancer cells.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Seattle, WA Undisclosed
USA
Seattle, WA Undisclosed
USA
Phone
Undisclosed
Email Address
Not Recorded
Overview
IsoBio, Inc. is a privately held radiotherapeutic development company focused on the development of antibody-isotope conjugates (AICs) for use in cancer treatment. AICs are monoclonal antibodies against both validated and novel tumor targets conjugated to radioactive isotopes to provide potent anti-tumor activity with reduced off-target side-effects.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Bruce Turner
Browse more venture capital transactions:
Prev: 7/28/2025: Positron venture capital transaction
Next: 7/28/2025: MapLight Therapeutics venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. All VC database entries on this site are sourced from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs